Year All2026202520242023202220212020201920182017201620152014 Abivax appoints Ana Sharma as Vice President, Global Head of Quality February 07, 2024 Read More Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease February 02, 2024 Read More Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 January 24, 2024 Read More Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months January 22, 2024 Read More Abivax 2024 Financial Communication Calendar January 04, 2024 Read More Abivax announces the resumption of its liquidity contract November 21, 2023 Read More Abivax meets the French “PEA-PME” eligibility criteria (in French) November 16, 2023 Read More Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference November 14, 2023 Read More Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market October 24, 2023 Read More Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market October 24, 2023 Read More
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease February 02, 2024 Read More
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 January 24, 2024 Read More
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months January 22, 2024 Read More
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference November 14, 2023 Read More
Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market October 24, 2023 Read More
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market October 24, 2023 Read More
